Synthetic Human Secretin in Children With Autism

Repligen

Status and phase: Completed; Phase 3

Conditions: Autism

Treatments: Drug: RG1068 (Synthetic Human Secretin)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00036244

RG1068-04

Details and patient eligibility

About

The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.

Sex: All

Ages: 32 to 59 months old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Autism

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind